Premium
Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry
Author(s) -
Danchin Nicolas,
Charpentier Guillaume,
Ledru François,
Vaur Laurent,
Guéret Pascal,
Hanania Guy,
Blanchard Didier,
Lablanche JeanMarc,
Genès Nathalie,
Cambou JeanPierre
Publication year - 2004
Publication title -
diabetes/metabolism research and reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.307
H-Index - 110
eISSN - 1520-7560
pISSN - 1520-7552
DOI - 10.1002/dmrr.498
Subject(s) - medicine , myocardial infarction , killip class , hyperlipidemia , diabetes mellitus , relative risk , cardiology , percutaneous coronary intervention , confidence interval , endocrinology
Background The cardiovascular effects of sulfonylureas (SU) in diabetic patients are controversial and it has been suggested that diabetic patients with acute myocardial infarction while on SU were at increased risk. Objectives To assess the in‐hospital outcome of patients with acute myocardial infarction according to the use of SU at the time of the acute episode. Methods Of 443 intensive care units in France, 369 (83%) prospectively collected all cases of infarction admitted within 48 h of symptom onset in November 2000. Results Among the 2320 patients included in the registry, 487 (21%) had diabetes, of whom 215 (44%) were on SU. Patients on SU were older and had a more frequent history of hyperlipidemia than those not receiving SU. Type and location of infarction were similar in the two groups, and there was no difference in Killip class on admission. In‐hospital mortality was lower in patients on SU (10.2%) than in those without SU (16.9%) ( p = 0.035). There was a trend toward less frequent ventricular fibrillation (2.3% vs 5.9%, p = 0.052). In two models of multivariate analyses, SU therapy was associated with decreased in‐hospital mortality (model 1: relative risk: 0.44, p = 0.012; model 2: relative risk: 0.37, p = 0.020). Conclusions In this nationwide registry reflecting real‐world practice, the use of sulfonylureas in diabetic patients was not associated with increased in‐hospital mortality. Copyright © 2004 John Wiley & Sons, Ltd.